KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

Background In the Children’s Oncology Group ANBL1221 phase 2 trial for patients with first relapse/first declaration of refractory high-risk neuroblastoma, irinotecan and temozolomide (I/T) combined with either temsirolimus (TEMS) or immunotherapy (the anti-GD2 antibody dinutuximab (DIN) and granulo...

Descripció completa

Dades bibliogràfiques

Autors principals:	Rajen Mody, KyungMann Kim, Paul M Sondel, Amy K Erbe, Julie Park, Sabah Servaes, Jen Birstler, Wendy B London, Jung-Tung Hung, Alice L Yu, John M Maris, Mitch B Diccianni, Arlene Naranjo, Fan F Zhang, Arika S Feils, Barry L Shulkin, Varsha Mathew, Marguerite T Parisi, Shahab Asgharzadeh, Rochelle Bagatell
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2023-02-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/11/2/e006530.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!